A neuroendocrine tumor of the stomach in a patient with Jervell-Lange-Nielsen syndrome – a case report

Česká verzia

Authors: O. Částka ¹; Z. Papík ¹; Š. Málková ¹; R. Kolářová ¹; V. Kozová ¹; B. Navrátilová ²
Authors place of work: Gastroenterologická a hepatologická poradna, Oblastní nemocnice Náchod a. s. ¹; Oddělení patologické anatomie a cytologie, Oblastní nemocnice Náchod a. s. ²
Published in the journal: Gastroent Hepatol 2026; 80(3): 234-238
Category: Gastrointestinální onkologie: kazuistika
doi: https://doi.org/10.48095/ccgh2026234

Summary

We present a rare case of a gastric neuroendocrine tumor in a young man with Jervell-Lange-Nielsen syndrome. The disease manifested clinically with nonspecific dyspeptic symptoms and was associated with achlorhydria in the absence of atrophic gastritis. The tumor infiltrating the gastric mucosa and submucosa was diagnosed based on histological and immunohistochemical examination of a biopsy specimen, which was confirmed positive for synaptophysin. No lymph node involvement or evidence of disease dissemination was found.

Keywords:

gastric neuroendocrine tumor – Jervell-Lange-Nielsen syndrome – achlorhydria

Zdroje

1. Rindi G, Klimstra DS, Abedi-Ardekani B et al. A common classification framework for neuroendocrine neoplasms: an IARC and WHO expert consensus proposal. Mod Pathol 2018; 31 (12): 1770–1786. doi: 10.1038/s41379-018-0110-y.

2. Modlin IM, Öberg K, Chung DC et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008; 9 (1): 61–72. doi: 10.1016/S1470-2045 (07) 70410-2.

3. O’Toole D, Grossman A, Gross D et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology 2009; 90 (2): 194–202. doi: 10.1159/00018228.

4. Panzuto F, Ramage J, Pritchard DM et al. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastroduodenal neuroendocrine tumors. J Neuroendocrinol 2023; 35 (3): e13306. doi: 10.1111/jne.13306.

5. Dell’Unto E, Esposito G, Rinzivillo M et al. Endoscopic resection of small type 3 gastric neuroendocrine tumors: a feasible option? Front Med (Lausanne) 2024; 11 : 1327864. doi: 10.3389/fmed.2024.1327864.

6. Laffi A, Lania AG, Ragni A et al. Gastric neuroendocrine neoplasms: a systematic review. Cancers (Basel) 2023; 15 (8): 2202. doi: 10.3390/cancers15082202.

7. Schwartz PJ, Crotti L, Insolia R. Long-QT syndrome: from genetics to management. Circ Arrhythm Electrophysiol 2012; 5 (4): 868–877. doi: 10.1161/CIRCEP.111.962019.

8. Tranebjaerg L, Samson RA, Green GE. Jervell and Lange-Nielsen syndrome. In: Adam MP, Everman DB, Mirzaa GM et al. (eds). GeneReviews. 2002 [online]. Dostupné z: https: //www.ncbi.nlm.nih.gov/books/NBK1405/.

9. Heitzmann D, Warth R. Physiology and pathophysiology of potassium channels in gastrointestinal epithelia. Physiol Rev 2008; 88 (3): 1119–1182. doi: 10.1152/physrev.00020.2007.

10. Warth R. Potassium channels in epithelial transport. Pflugers Arch 2003; 446 (5): 505–513. doi: 10.1007/s00424-003-1075-2.

11. Jeong HJ, Jeong JY, Kim JH et al. KCNQ1 potassium channels in gastric acid secretion and their potential pathophysiological relevance. World J Gastroenterol 2013; 19 (47): 8338–8343. doi: 10.3748/wjg.v19.i47.8338.

12. Ruszniewski P. Management of digestive neuroendocrine tumors: the state of the art. Dig Liver Dis 2004; 36 (5): 363–372. doi: 10.1016/j.dld.2003.12.024.

13. Iwase M. Gastrin and enterochromaffin-like cell hyperplasia in achlorhydria. J Gastroenterol Hepatol 2002; 17 (11): 1210–1216. doi: 10.1046/j.1440-1746.2002.02835.x.

14. Crawford J. Elevated serum gastrin levels in Jervell and Lange-Nielsen syndrome: A marker of severe KCNQ1 dysfunction. Heart Rhythm 2011. doi: 10.1016/J.HRTHM.2010.11.039.

15. Šachlová M. Neuroendokrinní nádory v gastroenterologické praxi. Gastroent Hepatol 2016; 70 (3): 220–225. doi: 10.14735/amgh2016csgh.info04.

16. Louthan O. Neuroendokrinní nádory žaludku. [online]. Dostupné z: https: //www.onkologiecs.cz/pdfs/xon/2012/06/05.pdf.

17. Hirasawa T. Long-term outcomes of endoscopic resection for type 3 gastric neuroendocrine tumors ≤10 mm. Dig Endosc 2021; 33 (5): 805–814. doi: 10.1111/den.13778.